[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-430006-105":59,"doc-detail-430006-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","richters-transformation-status-quo-and-quo-vadis","Richter’s transformation - status quo and quo vadis","","Despite major advances over the past decade for chronic lymphocytic leukemia (CLL), prognosis for Richter transformation (RT) remains poor, unfavorable, and difficult to control. Standard multiagent chemoimmunotherapy, often anthracycline-based, yields outcomes substantially worse than in de novo diffuse large B-cell lymphoma. Even with a growing number of novel targeted agents, reported study results still fail to achieve satisfactory control of this aggressively transformed CLL state.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/richters-transformation-status-quo-and-quo-vadis/430006/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/richters-transformation-status-quo-and-quo-vadis/430006.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is Richter transformation (RT) in CLL/SLL patients?","Question",{"text":113,"@type":114},"Richter transformation refers to the development of an aggressive lymphoma arising on a background of small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL). It is characterized by rapid and chaotic proliferation in specific lymph node or extra-nodal regions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How common is RT among CLL patients, and when does it usually occur?",{"text":118,"@type":114},"Approximately 2–10% of CLL patients experience RT, and it occurs more commonly during the course of disease than at diagnosis. Patients have an annual transition incidence to RT of roughly 0.5–1%.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is RT prognosis generally poor despite new therapies?",{"text":122,"@type":114},"RT typically shows poor overall survival and poor treatment response, especially with TP53 alterations and CDKN2A/2B codeletion. Outcomes remain dismal due to high resistance rates, limited durability of treatment, and barriers including affordability.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},430006,1790814718,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Annals of Hematology (2025) 104:6117–6130  \n[https://doi.org/10.1007/s00277-025-06622-5](https://doi.org/10.1007/s00277-025-06622-5)  \nREVIEW  \nRichter’s transformation: status quo and quo vadis  \nIbtesam M. Khalifa1,2  \nReceived: 13 August 2025 / Accepted: 7 September 2025 / Published online: 15 November 2025 © The Author(s) 2025  \nAbstract  \nDespite remarkable advancements in the last decade for individuals with chronic lymphocytic leukemia (CLL), the prognosis for those with Richter transformation (RT) remains poor, unfavorable and still challenging. Multiagent chemoimmunotherapy agents which are usually anthracycline based have been frequently employed; however, the outcomes are significantly inferior compared to those seen with identical regimens in de novo diffuse large B-cell lymphoma. Despite the emergence of numerous novel therapeutic agents in the last few years and yet still more to come, almost all studies outcomes are still not satisfactory to control this aggressively transformed CLL state.  \nKeywords Richter · Chronic lymphocytic leukemia · Targeted therapy · Lymphoma  \nIntroduction  \nThe development of an aggressive lymphoma on a background of small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL) is known as Richter transformation (RT) [1] .  \nRapid and chaotic proliferation of the malignant cells in specific lymph node or extra-nodal regions is a key characteristic of RT [2] .  \nAbout 2–10% ofCLL patients experience this potentially fatal complication, which usually occur more commonly during the course of the disease than at diagnosis [3, 4] .  \nPatients with CLL have an annual rate of incidence of transition to RT of roughly 0.5–1%[5] .  \nUsing the Surveillance, Epidemiology, and End Results (SEER) database of 74,116 patients with CLL/SLL diagnosed from 2000 to 2016, Elnair et al. conducted retrospective research and discovered that 530 of these patients experienced RT. In this study it was reported that the median age at RT diagnosis was 66 years, and the median interval between CLL/SLL diagnosis and RT development was  \n􀀍 Ibtesam M. Khalifa [imkhalifa@fcms.edu.sa](imkhalifa@fcms.edu.sa)  \n1 Clinical Sciences Department, MBBS Program, Fakeeh College for Medical Sciences, 21461 Jeddah, Saudi Arabia  \n2 Internal Medicine Department (Clinical Haematology Unit), Faculty of Medicine, Ain Shams University, Cairo, Egypt  \napproximately 4 years. Additionally, they noted that the median overall survival (OS) for RT patients was only 10 months [6] .  \nTo address concerns raised by early studies reporting high rates of RT in relapsed CLL patients treated with novel targeted agents, Hampel and colleagues conducted a study to determine whether these elevated RT incidences were truly attributable to novel targeted therapies or rather to the heavily pre-treated nature of the patient population. Their analysis compared RT incidence in two cohorts: patients treated during the pre-novel agent era and those treated in the novel agent era. The 1-year RT incidence rates were 0.3% and 0.2%, respectively suggesting no increased risk associated with novel agents. Importantly, the study concluded that patients receiving CLL/SLL-directed treatment in the novel agent era appear to have a lower risk of RT. This reduced risk may be explained by the absence of chemoimmunotherapy exposure among those who developed RT during the novel agent era [7] .  \nPatients with RT usually have poor overall survival and poor response to treatment; this is especially true for those with alterations in tumor suppressor p53 (TP53) and Codeletion of the contiguous gene cyclin-dependent kinase inhibitor 2A/2B (CDKN2A/2B) [8] .  \nPatients with CLL/SLL who experience B-symptoms, fast progressing asymmetric lymphadenopathy, or a significant increase in serum lactate dehydrogenase (LDH) should be suspected of having RT [9] .  \nRT could be either one of the following two subtypes, diffuse large B cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) . RT-D","cbCail5ERNPM6Avu","https://ap.wps.com/l/cbCail5ERNPM6Avu","pdf",1582340,14,"English","# Introduction\n# Pathogenesis","[{\"question\":\"What is Richter transformation (RT) in CLL/SLL patients?\",\"answer\":\"Richter transformation refers to the development of an aggressive lymphoma arising on a background of small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL). It is characterized by rapid and chaotic proliferation in specific lymph node or extra-nodal regions.\"},{\"question\":\"How common is RT among CLL patients, and when does it usually occur?\",\"answer\":\"Approximately 2–10% of CLL patients experience RT, and it occurs more commonly during the course of disease than at diagnosis. Patients have an annual transition incidence to RT of roughly 0.5–1%.\"},{\"question\":\"Why is RT prognosis generally poor despite new therapies?\",\"answer\":\"RT typically shows poor overall survival and poor treatment response, especially with TP53 alterations and CDKN2A/2B codeletion. Outcomes remain dismal due to high resistance rates, limited durability of treatment, and barriers including affordability.\"}]","Richter’s transformation - status quo and quo vadis | PDF",1790651637,35]